SPRY

Ars Pharmaceuticals Inc (SPRY) | Rumor.io

Ars Pharmaceuticals

SPRY

Attention (50-day avg)0%

Attention rank (50-day avg)#1,916

Bullish sentiment (50-day avg)62%

Price to earnings ratio168.3

Market capitalization410.7M

Earnings per share-2.18

Dividend yield (TTM)—

Revenue (annual)84.3M

Net income (annual)-171.3M

Social

What share of all stock conversation is about SPRY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Aug 14

The company's Neffy product has shown significant growth, with U.S. revenue increasing about 50% sequentially from Q1 and more than doubling YoY.
The company has made a strategy change to reduce spending and increase revenue, which has led to a reduction in SG&A expenses by ~40%.
The company's stock price has fluctuated due to concerns over the product's commercial viability and the company's cash burn rate, but some investors are optimistic about the company's potential.

Generated by AI

Sentiment

Of the messages about SPRY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	75% +20	72.55% +32.23	57.68% -6.55
Bearish	100%	25% -20	27.45% -32.23	42.32% +6.55

Bullish· Jan 10

$SPRY is expected to see a bright 2026 with opportunities arising from the differentiation of its product, Anaphylm, from competitors like Neffy.
International launches of $SPRY are expected to drive growth, with meaningful revenue expected in Q2 2026 from the UK, Japan, and China, and in Q1 2026 from Germany.
$SPRY's revenue growth is expected to continue, with SGA expenses stabilizing, as the company expands its reach and captures a larger share of the market.

Bearish· May 15

$SPRY's cash burn is astronomical, with $60M+ spent each quarter, and funds will last only until the end of 2026, creating a bad situation.
The company's business model is questionable, as it spent $72M, including $26M on selling and marketing expenses, to generate only $23M in revenue.
$SPRY's high debt of over $200M and lack of substantial revenue growth, combined with increasing competition and a new company president, make it overvalued and likely to drop in price.

Generated by AI

Topics

Of the messages about SPRY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	44.44%	62.33%
Analysts	—	0%	44.44%	13.46%
Technical Analysis	—	100%	11.11%	13.9%
Earnings	—	0%	0%	9%
Controversies	—	0%	0%	1.22%
Macro	—	0%	0%	0.09%

Sep 20

The FDA issued a Complete Response Letter (CRL) to ARS Pharmaceuticals, requesting additional studies for its epinephrine nasal spray, neffy.
The CRL requires ARS Pharmaceuticals to conduct a pharmacokinetic/pharmacodynamic study assessing repeat doses of neffy compared to epinephrine injection products under allergen-induced allergic rhinitis conditions.
The FDA's decision was a setback for ARS Pharmaceuticals, with shares of SPRY falling by almost 55% in intraday trading.

Generated by AI

Community

Of the messages about SPRY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	91.07%	90.38%	65.1%
Newcomers	0%	8.93%	9.62%	34.9%

Regulars· Aug 13

The majority of SPRY's Q2 losses came from $77 million spent on broad consumer awareness, which can be corrected with a more targeted sales strategy, and the company has strong margins with cost of goods sold at around $12 million.
SPRY's net loss is $62.3 million, with revenue of $33.7 million, and the company is expected to reach cash flow breakeven by the end of 2027.
The Q2 earnings beat revenue estimates, but missed EPS estimates, with adjusted EPS at $(0.63) vs an estimated $(0.48), and the company has a 5% total epinephrine market share and 8% in targeted accounts.

Newcomers· Mar 9

Newcomers are excited about ARS Pharmaceuticals' ($SPRY) strong first-year revenue of $72.2M, driven by neffy's adoption in the US market.
The company has a solid cash position of $245M, which provides a runway to break-even and supports further growth.
The release of Phase 2b data is expected mid-2026, which could be a catalyst for the stock, and sector rotation is likely, with options flow anticipated.

Generated by AI

News

Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

2d agoBarchart.com

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026

4d agoBarchart.com

Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

5d agoThe Globe and Mail

Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026

7d agoBarchart.com

Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026

Detailed price information for Bank of America Corp (BAC-N) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Kaplan Fox & Kilsheimer LLP Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before October 5, 2026

NewMediaWire Press Release.

8d agoThe Globe and Mail

Also Discussed

Investors talking about SPRY also mention

#	Name	Attention
1	Aquestive Therapeutics Inc.AQST	0%+0
2	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
3	DAWN - Day One Biopharmaceuticals, Inc.	——
4	Arcutis Biotherapeutics, Inc.ARQT	0%+0
5	Replimune Group, Inc.REPL	0%0
6	Journey Medical Corp. Common StockDERM	0%new
7	Zentalis Pharmaceuticals, Inc.ZNTL	0%new
8	Kura Oncology, Inc.KURA	0%+0
9	Tarsus Pharmaceuticals Inc.TARS	0%new
10	TScan Therapeutics, Inc.TCRX	0%0

Ars Pharmaceuticals Inc

Healthcare
Biotechnology

Ars Pharmaceuticals Inc. specializes in the biopharmaceutical sector, focusing on the development of innovative, self-administered therapeutics aimed at improving patient outcomes. The company's primary purpose is to advance medical solutions for allergy-related indications, enhancing safety and convenience for patients affected by conditions such as allergic reactions requiring rapid intervention. Notable for its emphasis on creating user-friendly delivery mechanisms, Ars Pharmaceuticals tailors its offerings to both patients and healthcare professionals seeking reliable and effective emergency treatments. By addressing critical needs within the healthcare industry, Ars Pharmaceuticals plays a significant role in expanding options in allergy treatment and management. Its contributions to the medical field underscore its ongoing commitment to transforming therapeutic landscapes and meeting pressing health challenges.

Website

Location

11682 El Camino Real

San Diego, CA, 92130

United States

Social

What share of all stock conversation is about SPRY?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Aug 14

The company's Neffy product has shown significant growth, with U.S. revenue increasing about 50% sequentially from Q1 and more than doubling YoY.
The company has made a strategy change to reduce spending and increase revenue, which has led to a reduction in SG&A expenses by ~40%.
The company's stock price has fluctuated due to concerns over the product's commercial viability and the company's cash burn rate, but some investors are optimistic about the company's potential.

Generated by AI

Sentiment

Of the messages about SPRY that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	75% +20	72.55% +32.23	57.68% -6.55
Bearish	100%	25% -20	27.45% -32.23	42.32% +6.55

Bullish· Jan 10

$SPRY is expected to see a bright 2026 with opportunities arising from the differentiation of its product, Anaphylm, from competitors like Neffy.
International launches of $SPRY are expected to drive growth, with meaningful revenue expected in Q2 2026 from the UK, Japan, and China, and in Q1 2026 from Germany.
$SPRY's revenue growth is expected to continue, with SGA expenses stabilizing, as the company expands its reach and captures a larger share of the market.

Bearish· May 15

$SPRY's cash burn is astronomical, with $60M+ spent each quarter, and funds will last only until the end of 2026, creating a bad situation.
The company's business model is questionable, as it spent $72M, including $26M on selling and marketing expenses, to generate only $23M in revenue.
$SPRY's high debt of over $200M and lack of substantial revenue growth, combined with increasing competition and a new company president, make it overvalued and likely to drop in price.

Generated by AI

Topics

Of the messages about SPRY that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	44.44%	62.33%
Analysts	—	0%	44.44%	13.46%
Technical Analysis	—	100%	11.11%	13.9%
Earnings	—	0%	0%	9%
Controversies	—	0%	0%	1.22%
Macro	—	0%	0%	0.09%

Sep 20

The FDA issued a Complete Response Letter (CRL) to ARS Pharmaceuticals, requesting additional studies for its epinephrine nasal spray, neffy.
The CRL requires ARS Pharmaceuticals to conduct a pharmacokinetic/pharmacodynamic study assessing repeat doses of neffy compared to epinephrine injection products under allergen-induced allergic rhinitis conditions.
The FDA's decision was a setback for ARS Pharmaceuticals, with shares of SPRY falling by almost 55% in intraday trading.

Generated by AI

Community

Of the messages about SPRY, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	91.07%	90.38%	65.1%
Newcomers	0%	8.93%	9.62%	34.9%

Regulars· Aug 13

The majority of SPRY's Q2 losses came from $77 million spent on broad consumer awareness, which can be corrected with a more targeted sales strategy, and the company has strong margins with cost of goods sold at around $12 million.
SPRY's net loss is $62.3 million, with revenue of $33.7 million, and the company is expected to reach cash flow breakeven by the end of 2027.
The Q2 earnings beat revenue estimates, but missed EPS estimates, with adjusted EPS at $(0.63) vs an estimated $(0.48), and the company has a 5% total epinephrine market share and 8% in targeted accounts.

Newcomers· Mar 9

Newcomers are excited about ARS Pharmaceuticals' ($SPRY) strong first-year revenue of $72.2M, driven by neffy's adoption in the US market.
The company has a solid cash position of $245M, which provides a runway to break-even and supports further growth.
The release of Phase 2b data is expected mid-2026, which could be a catalyst for the stock, and sector rotation is likely, with options flow anticipated.

Generated by AI

Ars Pharmaceuticals

Social

Aug 14

Bullish· Jan 10

Bearish· May 15

Sep 20

Regulars· Aug 13

Newcomers· Mar 9

Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026

Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026

Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026

Kaplan Fox & Kilsheimer LLP Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before October 5, 2026

Also Discussed

Ars Pharmaceuticals Inc

Company Information

Location

Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before the Deadline on October 5, 2026

Kaplan Fox Encourages Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to Contact the Firm to Learn About Their Legal Rights

Kaplan Fox Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Seek Leadership in a Securities Fraud Lawsuit by October 5, 2026

Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026

Kaplan Fox & Kilsheimer LLP Encourages ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors to Contact the Firm Before October 5, 2026

Also Discussed

Social

Aug 14

Bullish· Jan 10

Bearish· May 15

Sep 20

Regulars· Aug 13

Newcomers· Mar 9